A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Stopped early · Phase 1/Phase 2
Conditions studied: Unresectable Stage III or Stage IV Melanoma
In brief
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.
Key facts
- Study ID
- NCT02413827
- Run by
- Celldex Therapeutics
- People needed
- 9
- Starts
- 2015-04-01
- Expected to finish
- 2016-11-09
- Last updated by the study team
- 2017-04-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Pacific Medical Center Research Institute — San Francisco, California, United States
- Sutter Pacific Medical Foundation — Santa Rosa, California, United States
- University of Colorado — Aurora, Colorado, United States
- Georgetown University School of Medicine — Washington D.C., District of Columbia, United States
- University of Chicago — Chicago, Illinois, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- Tennessee Oncology Sarah Cannon Research Institute — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.